Demographic and clinical characteristics of current comorbid psychiatric disorders in a randomized clinical trial for adults with stimulant use disorders

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study aimed to determine if current comorbid psychiatric disorders differ in adults with cocaine use disorder, other stimulant (primarily methamphetamine) use disorder, or both, and identify demographic and clinical characteristics in those with increasing numbers of comorbid disorders. Baseline data from a randomized controlled trial beginning in residential settings (N=302) was used. Mood disorders were present in 33.6%, and anxiety disorders in 29.6%, with no differences among stimulant use disorder groups. Panic disorder was more frequently present with other stimulant use disorder. Those with two or more comorbid psychiatric disorders were more often female, White, had more symptoms of depression, greater propensity and risk for suicidal behavior, lower functioning in psychiatric and family domains, lower quality of life, more symptoms with stimulant abstinence and greater likelihood of marijuana dependence. Those with one or more comorbid disorders had more medical disorder burden, lower cognitive and physical functioning, greater pain, and higher rates of other drug dependence. With current comorbid psychiatric disorders, the morbidity of stimulant use disorders increases. Use of validated assessments near treatment entry, and a treatment plan targeting not only substance use and comorbid psychiatric disorders, but functional impairments, medical disorder burden and pain, may be useful.

Original languageEnglish (US)
Pages (from-to)136-141
Number of pages6
JournalPsychiatry Research
Volume246
DOIs
StatePublished - Dec 30 2016

Fingerprint

Psychiatry
Randomized Controlled Trials
Demography
Marijuana Abuse
Somatoform Disorders
Methamphetamine
Panic Disorder
Risk-Taking
Anxiety Disorders
Mood Disorders
Cocaine
Substance-Related Disorders
Quality of Life
Depression
Morbidity
Pain
Therapeutics

Keywords

  • Cocaine
  • Comorbidities
  • Methamphetamine
  • Panic disorder
  • Residential treatment
  • Substance use disorder

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

@article{ea0b973ed5b841638a89696d8a8e1ad1,
title = "Demographic and clinical characteristics of current comorbid psychiatric disorders in a randomized clinical trial for adults with stimulant use disorders",
abstract = "This study aimed to determine if current comorbid psychiatric disorders differ in adults with cocaine use disorder, other stimulant (primarily methamphetamine) use disorder, or both, and identify demographic and clinical characteristics in those with increasing numbers of comorbid disorders. Baseline data from a randomized controlled trial beginning in residential settings (N=302) was used. Mood disorders were present in 33.6{\%}, and anxiety disorders in 29.6{\%}, with no differences among stimulant use disorder groups. Panic disorder was more frequently present with other stimulant use disorder. Those with two or more comorbid psychiatric disorders were more often female, White, had more symptoms of depression, greater propensity and risk for suicidal behavior, lower functioning in psychiatric and family domains, lower quality of life, more symptoms with stimulant abstinence and greater likelihood of marijuana dependence. Those with one or more comorbid disorders had more medical disorder burden, lower cognitive and physical functioning, greater pain, and higher rates of other drug dependence. With current comorbid psychiatric disorders, the morbidity of stimulant use disorders increases. Use of validated assessments near treatment entry, and a treatment plan targeting not only substance use and comorbid psychiatric disorders, but functional impairments, medical disorder burden and pain, may be useful.",
keywords = "Cocaine, Comorbidities, Methamphetamine, Panic disorder, Residential treatment, Substance use disorder",
author = "Diane Warden and Katherine Sanchez and Tracy Greer and Thomas Carmody and Robrina Walker and {dela Cruz}, Adriane and Marisa Toups and Chad Rethorst and Trivedi, {Madhukar H.}",
year = "2016",
month = "12",
day = "30",
doi = "10.1016/j.psychres.2016.09.007",
language = "English (US)",
volume = "246",
pages = "136--141",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Demographic and clinical characteristics of current comorbid psychiatric disorders in a randomized clinical trial for adults with stimulant use disorders

AU - Warden, Diane

AU - Sanchez, Katherine

AU - Greer, Tracy

AU - Carmody, Thomas

AU - Walker, Robrina

AU - dela Cruz, Adriane

AU - Toups, Marisa

AU - Rethorst, Chad

AU - Trivedi, Madhukar H.

PY - 2016/12/30

Y1 - 2016/12/30

N2 - This study aimed to determine if current comorbid psychiatric disorders differ in adults with cocaine use disorder, other stimulant (primarily methamphetamine) use disorder, or both, and identify demographic and clinical characteristics in those with increasing numbers of comorbid disorders. Baseline data from a randomized controlled trial beginning in residential settings (N=302) was used. Mood disorders were present in 33.6%, and anxiety disorders in 29.6%, with no differences among stimulant use disorder groups. Panic disorder was more frequently present with other stimulant use disorder. Those with two or more comorbid psychiatric disorders were more often female, White, had more symptoms of depression, greater propensity and risk for suicidal behavior, lower functioning in psychiatric and family domains, lower quality of life, more symptoms with stimulant abstinence and greater likelihood of marijuana dependence. Those with one or more comorbid disorders had more medical disorder burden, lower cognitive and physical functioning, greater pain, and higher rates of other drug dependence. With current comorbid psychiatric disorders, the morbidity of stimulant use disorders increases. Use of validated assessments near treatment entry, and a treatment plan targeting not only substance use and comorbid psychiatric disorders, but functional impairments, medical disorder burden and pain, may be useful.

AB - This study aimed to determine if current comorbid psychiatric disorders differ in adults with cocaine use disorder, other stimulant (primarily methamphetamine) use disorder, or both, and identify demographic and clinical characteristics in those with increasing numbers of comorbid disorders. Baseline data from a randomized controlled trial beginning in residential settings (N=302) was used. Mood disorders were present in 33.6%, and anxiety disorders in 29.6%, with no differences among stimulant use disorder groups. Panic disorder was more frequently present with other stimulant use disorder. Those with two or more comorbid psychiatric disorders were more often female, White, had more symptoms of depression, greater propensity and risk for suicidal behavior, lower functioning in psychiatric and family domains, lower quality of life, more symptoms with stimulant abstinence and greater likelihood of marijuana dependence. Those with one or more comorbid disorders had more medical disorder burden, lower cognitive and physical functioning, greater pain, and higher rates of other drug dependence. With current comorbid psychiatric disorders, the morbidity of stimulant use disorders increases. Use of validated assessments near treatment entry, and a treatment plan targeting not only substance use and comorbid psychiatric disorders, but functional impairments, medical disorder burden and pain, may be useful.

KW - Cocaine

KW - Comorbidities

KW - Methamphetamine

KW - Panic disorder

KW - Residential treatment

KW - Substance use disorder

UR - http://www.scopus.com/inward/record.url?scp=84988933736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988933736&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2016.09.007

DO - 10.1016/j.psychres.2016.09.007

M3 - Article

VL - 246

SP - 136

EP - 141

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

ER -